Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Neoadjuvant Therapy
  •  Central Nervous System Tumors
  •  Chemotherapy and Radiotherapy
  •  Gynecological Cancers
  •  Prostate Cancer
  •  Colon Cancer
  •  Surgical Oncology
  •  Thoracic Oncology

Abstract

Citation: Clin Oncol. 2017;2(1):1250.DOI: 10.25107/2474-1663.1250

Benefits of Metastasectomy in Esophagogastric Cancer

MacCormick S, Chong KC, Sullivan HO, Hamill M and MacCormick R

Department of Oncology, Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada

*Correspondance to: MacCormick R 

 PDF  Full Text Case Report | Open Access

Abstract:

Background: Esophagogastric cancer is the second most common cause of cancer related deaths worldwide and often presents late with approximately 32% of US patients presenting with distant metastases. The current guidelines for metastases of gastric cancer involve palliative chemotherapy and supportive measures. However, the median overall survival with these guidelines is less than 1 year. Performing a gastrectomy, along with metastasectomy and chemotherapy shows the highest median overall survival of 28.0 months for metastatic gastric cancer. The aim of this systematic review is to determine whether performing metastasectomies increases overall, 1year and 3year survival in metastatic esophagogastric carcinoma.Methods: A systematic review was performed. Inclusion and exclusion criteria were developed, specific outcomes were identified (overall, 1 and 3 year survival for esophagogastric cancer with and without metastasectomies) and a search strategy with key words for Embase and Google Scholar was employed.Results: 37 articles were found through the Embase database search and 20 additional sources were identified via independent Google Scholar searches. After careful review of the titles, abstracts and full texts by 2 separate reviewers, 6 articles were included for systematic review. The median overall survival, 1-year survival and 3-year survival were greater for patients who received gastrectomy with metastasectomy compared to gastrectomy without metastasectomy, with the exception of study that did not concur with a greater 1-year survival in metastasectomy patients.Conclusions: This systematic review, suggests that surgery for resection of oligometastases improves prognosis. However, randomized, larger scale studies are recommended.

Keywords:

Cite the Article:

MacCormick S, Chong KC, Sullivan HO, Hamill M, MacCormick R. Benefits of Metastasectomy in Esophagogastric Cancer. Clin Oncol. 2017; 2: 1250.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Removal of a Huge Uterine Mass, Weighing 11000 Grams, In an Elderly Woman with a Minimally Invasive Surgical Approach: Feasibility and Safety
 Abstract  PDF  Full Text
Breast MR Imaging Helps Differentiate Malignant and Benign Mammographic Microcalcifications: A Study Based on the 5th Edition of BI-RADS
 Abstract  PDF  Full Text
View More...